clinical trial · NCT06775379
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Major Depressive DisorderAzetukalnerPlacebo
brief summary
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
started
Dec 20, 2024
primary completion
Aug 1, 2026
completion
Oct 1, 2026
last updated
Oct 22, 2025
official title
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol